Why the study?
It was unknown whether CTO-PCI improves QoL and MACCE in order to guide future clinical recommendations.
Does CTO-PCI improve QoL and MACCE in patients with chronic total coronary occlusions with myocardial ischemia compared to optimal medical therapy?
Does CTO-PCI improve QoL and MACCE in patients with chronic total coronary occlusions with myocardial ischemia compared to optimal medical therapy?
The ISCHEMIA-CTO trial will provide randomized data on whether revascularization improves outcomes and quality of life compared to medical therapy in patients with CTO and ischemia.
Answers are grounded in this paper and cite their sources.
May guide future CTO revascularization decisions; first RCT testing PCI versus medical therapy on outcomes and QoL.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Råmunddal et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: